Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Petar M. Seferović*, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Çavuşoğlu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferović, Pardeep S. Jhund, Giuseppe Dattilo, Jelena Čelutkiene, Massimo Piepoli, Brenda MouraOvidiu Chioncel, Tuvia Ben Gal, Stefan Heymans, Rudolf A. de Boer, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R. Lyon, Piotr Ponikowski, Mitja Lainščak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars Lund, Gerasimos S. Filippatos, Frank Ruschitzka, Andrew J.S. Coats, Giuseppe M.C. Rosano

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.

Original languageEnglish
Pages (from-to)1495-1503
Number of pages9
JournalEuropean Journal of Heart Failure
Volume22
Issue number9
Early online date05 Aug 2020
DOIs
Publication statusPublished - 01 Sep 2020

Bibliographical note

Publisher Copyright:
© 2020 European Society of Cardiology

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

  • Cardiovascular outcomes
  • Heart failure
  • Quality of life
  • Sodium–glucose co-transporter 2 inhibitors
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology'. Together they form a unique fingerprint.

Cite this